source
- J&J to buy Firefly Bio for $1 billion to boost KRAS inhibitor programJ&J announced Monday it will acquire biotech startup Firefly Bio for $1 billion, aiming to broaden its KRAS inhibitor portfolio. The move follows recent data from Revolution Medicines showing a KR…
- Tango to launch Phase 3 trial in pancreatic cancer after promising combo resultsTango announced plans to begin a Phase 3 trial testing a combination therapy for pancreatic cancer. The decision follows data presented at the American Society of Clinical Oncology meeting, where…